AR030179A1 - Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico - Google Patents
Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceuticoInfo
- Publication number
- AR030179A1 AR030179A1 ARP000106887A ARP000106887A AR030179A1 AR 030179 A1 AR030179 A1 AR 030179A1 AR P000106887 A ARP000106887 A AR P000106887A AR P000106887 A ARP000106887 A AR P000106887A AR 030179 A1 AR030179 A1 AR 030179A1
- Authority
- AR
- Argentina
- Prior art keywords
- receptor
- abl
- pdgf
- product
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Una combinacion que comprende (a) al menos un inhibidor de tirosinquinasa del receptor abl, del receptor PDGF-R, y/o del receptor de Kit, y (b) al menos un compuesto orgánico capaz de enlazarse con glicoproteína ácido-alfa1 (AGP); o sales farmacéuticamente aceptables de cualquier componente (a), (b), o (a) y (b), si está presente al menos un grupo formador de sal, y un vehículo farmacéuticamente aceptable, así como a productos farmacéuticos destinados a terapias relacionadas con estados de enfermedad que respondan a la inhibicion de tirosinquinasa del receptor abl, del receptor PDGF, y/o del receptor de kit. En particular se refiere a combinaciones y productos que comprenden un inhibidor de tirosinquinasa del receptor abl, del receptor PDGF y/o del receptor de kit con un compuesto orgánico capaz de enlazarse con AGP, en una combinacion fija, o para su administracion cronologicamente escalonada o simultánea, y al uso combinado de ambas clases de compuestos, para producir productos farmacéuticos ya sea en una combinacion fija, o para su administracion cronologicamente escalonada o simultánea, para el tratamiento de enfermedades proliferativas, especialmente enfermedades tumorales, especialmente aquellas que se puedan tratar mediante la inhibicion de la actividad de tirosinquinasa del receptor abl, del receptor PDGF, y/o del receptor de kit.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1999MI002711A ITMI992711A1 (it) | 1999-12-27 | 1999-12-27 | Composti organici |
Publications (1)
Publication Number | Publication Date |
---|---|
AR030179A1 true AR030179A1 (es) | 2003-08-13 |
Family
ID=11384195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000106887A AR030179A1 (es) | 1999-12-27 | 2000-12-22 | Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico |
Country Status (18)
Country | Link |
---|---|
US (2) | US20030125343A1 (es) |
EP (1) | EP1250140B1 (es) |
JP (1) | JP2003523325A (es) |
CN (1) | CN1304005C (es) |
AR (1) | AR030179A1 (es) |
AT (1) | ATE432069T1 (es) |
AU (1) | AU2171901A (es) |
BR (1) | BR0016817A (es) |
CA (1) | CA2394944A1 (es) |
CO (1) | CO5271710A1 (es) |
DE (1) | DE60042283D1 (es) |
ES (1) | ES2326307T3 (es) |
HK (1) | HK1050993A1 (es) |
IT (1) | ITMI992711A1 (es) |
PE (1) | PE20010991A1 (es) |
PT (1) | PT1250140E (es) |
TW (1) | TWI246917B (es) |
WO (1) | WO2001047507A2 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60130017T2 (de) * | 2000-11-22 | 2008-05-15 | Novartis Ag | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität |
US6878697B2 (en) | 2001-06-21 | 2005-04-12 | Ariad Pharmaceuticals, Inc. | Phenylamino-pyrimidines and uses thereof |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
US7323469B2 (en) | 2001-08-07 | 2008-01-29 | Novartis Ag | 7H-pyrrolo[2,3-d]pyrimidine derivatives |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
MXPA04003878A (es) * | 2001-10-25 | 2004-07-08 | Novartis Ag | Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2. |
GB0201508D0 (en) | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
US20060128720A1 (en) * | 2002-03-21 | 2006-06-15 | Kufe Donald W | Inhibition of cell death responses induced by oxidative stress |
AU2007201830C1 (en) * | 2002-04-23 | 2017-09-07 | Novartis Pharma Ag | High drug load tablet |
GB0209265D0 (en) * | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
US20060052387A1 (en) * | 2002-06-26 | 2006-03-09 | Marsh Clay B | Organic compounds |
BR0312821A (pt) * | 2002-07-24 | 2005-04-19 | Akira Ohtsuru | 4-(4-metil-piperazin-1-il-metil)-n-[(4-metil-3-(4-piridin-3-i l)-pirimidin-2-il-amino)-fenil]-benzamida para tratar câncer anaplásico da tireóide |
EP1542989B1 (en) * | 2002-07-31 | 2007-04-18 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
ATE380810T1 (de) * | 2002-10-09 | 2007-12-15 | Critical Outcome Technologies | Protein-tyrosine-kinase-inhibitoren |
AU2003268185A1 (en) * | 2003-08-25 | 2005-04-11 | Dana-Farber Cancer Institute Inc. | Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias |
CN100467064C (zh) * | 2003-09-19 | 2009-03-11 | 诺瓦提斯公司 | 伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用 |
TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
PL1720853T3 (pl) † | 2004-02-11 | 2016-06-30 | Natco Pharma Ltd | Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania |
US7358250B2 (en) | 2004-06-29 | 2008-04-15 | Amgen Inc. | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity |
JP2008508358A (ja) * | 2004-08-02 | 2008-03-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物 |
ATE519759T1 (de) | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
US20070059359A1 (en) * | 2005-06-07 | 2007-03-15 | Thomas Backensfeld | Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof |
US20060275365A1 (en) * | 2005-06-07 | 2006-12-07 | Thomas Backensfeld | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof |
US20080214445A1 (en) * | 2005-06-23 | 2008-09-04 | Sebastien Bihorel | Method of Treating a Solid Tumor Disease Comprising Administering a Combination Comprising Imatinib and an Inhibitor of an Efflux Pump Active at the Blood Brain Barrier or Demethyl Imatinib |
RU2441869C2 (ru) * | 2005-12-21 | 2012-02-10 | Эбботт Лэборетриз | Противовирусные соединения |
EP1971611B1 (en) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Anti-viral compounds |
ATE475660T1 (de) | 2005-12-21 | 2010-08-15 | Abbott Lab | Antivirale verbindungen |
ES2458291T3 (es) * | 2006-04-20 | 2014-04-30 | Janssen Pharmaceutica Nv | Derivados de amidas aromáticas como inhibidores de la cinasa C-KIT |
AU2007269540B2 (en) * | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
EP2121681B1 (en) | 2007-01-11 | 2015-04-15 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
US20080248548A1 (en) * | 2007-04-09 | 2008-10-09 | Flynn Daniel L | Modulation of protein functionalities |
WO2009042803A1 (en) * | 2007-09-25 | 2009-04-02 | Teva Pharmaceutical Industries Ltd. | Imatinib compositions |
WO2009079797A1 (en) * | 2007-12-26 | 2009-07-02 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
EA201070841A1 (ru) | 2008-01-11 | 2011-02-28 | Натко Фарма Лимитед | НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
KR101956261B1 (ko) | 2008-05-21 | 2019-03-08 | 어리어드 파마슈티칼스, 인코포레이티드 | 키나아제 억제제로서 포스포러스 유도체 |
EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
CA2744563A1 (en) | 2008-12-12 | 2010-06-17 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
ITRM20090578A1 (it) * | 2009-11-10 | 2011-05-11 | Noi Per Voi Onlus | Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti. |
EP2552915B1 (en) | 2010-04-01 | 2017-07-19 | Critical Outcome Technologies Inc. | Compounds for the treatment of hiv |
AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
TR201010618A2 (tr) * | 2010-12-20 | 2012-07-23 | Bi̇lgi̇ç Mahmut | İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi |
PL394169A1 (pl) | 2011-03-09 | 2012-09-10 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania |
JP5999177B2 (ja) | 2011-05-04 | 2016-09-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
EP2817030A1 (en) | 2012-02-21 | 2014-12-31 | Ranbaxy Laboratories Limited | Stable dosage forms of imatinib mesylate |
WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
WO2017078647A1 (en) | 2015-11-05 | 2017-05-11 | Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi | Pharmaceutical compositions of imatinib |
EP3257499A1 (en) | 2016-06-17 | 2017-12-20 | Vipharm S.A. | Process for preparation of imatinib methanesulfonate capsules |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587459A (en) * | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
US20030069174A1 (en) * | 1997-03-10 | 2003-04-10 | Ludwig Pichler | Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation |
CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
WO2001004125A1 (fr) * | 1999-07-13 | 2001-01-18 | Kyowa Hakko Kogyo Co., Ltd. | Derives de staurosporine |
DZ3248A1 (fr) * | 1999-12-10 | 2001-06-14 | Pfizer Prod Inc | Composés à base de pyrrolo[2,3-d]pyrimidine |
-
1999
- 1999-12-27 IT IT1999MI002711A patent/ITMI992711A1/it unknown
-
2000
- 2000-12-08 TW TW089126229A patent/TWI246917B/zh active
- 2000-12-22 AU AU21719/01A patent/AU2171901A/en not_active Abandoned
- 2000-12-22 CO CO00097404A patent/CO5271710A1/es not_active Application Discontinuation
- 2000-12-22 AT AT00985244T patent/ATE432069T1/de active
- 2000-12-22 PE PE2000001393A patent/PE20010991A1/es not_active Application Discontinuation
- 2000-12-22 BR BR0016817-3A patent/BR0016817A/pt not_active Application Discontinuation
- 2000-12-22 CA CA002394944A patent/CA2394944A1/en not_active Abandoned
- 2000-12-22 JP JP2001548102A patent/JP2003523325A/ja active Pending
- 2000-12-22 AR ARP000106887A patent/AR030179A1/es not_active Application Discontinuation
- 2000-12-22 PT PT00985244T patent/PT1250140E/pt unknown
- 2000-12-22 EP EP00985244A patent/EP1250140B1/en not_active Expired - Lifetime
- 2000-12-22 DE DE60042283T patent/DE60042283D1/de not_active Expired - Lifetime
- 2000-12-22 US US10/169,035 patent/US20030125343A1/en not_active Abandoned
- 2000-12-22 CN CNB008178976A patent/CN1304005C/zh not_active Expired - Fee Related
- 2000-12-22 ES ES00985244T patent/ES2326307T3/es not_active Expired - Lifetime
- 2000-12-22 WO PCT/EP2000/013161 patent/WO2001047507A2/en active Search and Examination
-
2003
- 2003-03-12 HK HK03101801.4A patent/HK1050993A1/zh unknown
-
2009
- 2009-03-04 US US12/397,374 patent/US20090221519A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1250140A2 (en) | 2002-10-23 |
JP2003523325A (ja) | 2003-08-05 |
ITMI992711A0 (it) | 1999-12-27 |
WO2001047507A3 (en) | 2002-04-04 |
CN1414858A (zh) | 2003-04-30 |
US20030125343A1 (en) | 2003-07-03 |
CO5271710A1 (es) | 2003-04-30 |
CN1304005C (zh) | 2007-03-14 |
ATE432069T1 (de) | 2009-06-15 |
EP1250140B1 (en) | 2009-05-27 |
ES2326307T3 (es) | 2009-10-07 |
CA2394944A1 (en) | 2001-07-05 |
BR0016817A (pt) | 2002-10-01 |
AU2171901A (en) | 2001-07-09 |
US20090221519A1 (en) | 2009-09-03 |
TWI246917B (en) | 2006-01-11 |
DE60042283D1 (de) | 2009-07-09 |
PE20010991A1 (es) | 2001-10-23 |
ITMI992711A1 (it) | 2001-06-27 |
HK1050993A1 (zh) | 2003-07-18 |
PT1250140E (pt) | 2009-08-24 |
WO2001047507A2 (en) | 2001-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR030179A1 (es) | Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico | |
Harrington et al. | Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high-risk patients with resected squamous cell carcinoma of the head and neck: a phase III, randomized, double-blind, placebo-controlled study. | |
AR048502A1 (es) | Sinergia terapeutica de compuestos anti-cancer | |
CR8181A (es) | Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer | |
BRPI0612845A8 (pt) | composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador | |
ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
BRPI0606996A2 (pt) | combinação de compostos orgánicos, uso da mesma e composição farmacêutica | |
AR047988A1 (es) | Combinaciones antineoplásicas de cci-779 y rituximab | |
CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
CR9518A (es) | Eliminacion de poblacion celular heterogenea o mezclada en tumores | |
CY1110013T1 (el) | Συνδυασμοι για θεραπεια πολλαπλου μυελωματος | |
WO2011031474A3 (en) | Use of metformin in cancer treatment and prevention | |
AR065092A1 (es) | TERAPIA DE COMBINACIoN CON INHIBIDORES DE LA ANGIOGÉNESIS | |
AR044039A1 (es) | Combinaciones antineoplasicas | |
BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
AR074778A1 (es) | Composicion farmaceutica, con anticuerpo monoclonal humano anti - igf-ir. | |
WO2003063787A3 (en) | Non-steroidal analogs of 2-methoxyestradiol | |
CR20190429A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA-DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
AR021912A1 (es) | Uso de apomorfina para el tratamiento de la disfuncion erectil organica en varones | |
CU20090007A6 (es) | Un compuesto farmacéutico y un proceso del mismo | |
RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
AR049135A1 (es) | Composicion,metodo, kit y tratamiento con oxaliplatino y un inhibidor del egfr,como erlotinib | |
BRPI0514187A (pt) | composto, e, droga preventiva ou uma droga terapêutica | |
BRPI0715609A2 (pt) | Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |